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A B S T R A C T
In patients with a cryptogenic stroke the prevalence of a patent foramen ovale (PFO) 
is increased to approximately 50% compared with a 25%-30% prevalence rate in the 
general population. This leads to a plausible assumption that a considerable number 
of strokes could potentially be attributed to a PFO, most likely due to paradoxical 
embolism. It is estimated that the risk for an embolic stroke due to the presence of 
a PFO may be 9-fold higher than that related to hypertension, diabetes or hypercho-
lesterolemia. Furthermore, in the presence of an interatrial septal aneurysm (IASA), 
this risk may even be 30-fold higher. The management of patients with a cryptogenic 
stroke and a PFO is currently based on antithrombotic or anti-platelet therapy, how-
ever the recurrence rate remains high (4-25%), and this has led to the recommenda-
tion of percutaneous PFO closure, which is now effected via a simple and relatively 
safe technique, which appears to reduce recurrences to 0-5%. However, the studies 
which provide such favorable data are only retrospective, which means that we are in 
dire need of prospective randomized studies that compare the two therapeutic ap-
proaches, before the interventional method is more widely adopted. 
In addition to cryptogenic stroke, the presence of a PFO has been also associated, 
among other conditions, with bouts of migraine and its percutaneous closure has been 
shown, albeit via retrospective and observational data, to eliminate or significantly 
improve this common condition. The only prospective randomized trial available 
(MIST trial) failed to show conclusively the superiority of PFO closure to medical 
treatment with regards to elimination of migraine. 
Another large group of patients undergoing percutaneous closure of an interatrial 
communication are those with a secundum atrial septal defect (ASD). The majority 
of these patients, at least those having defects as large as 35-38 mm and an adequate 
rim to support a closure device, can now be successfully submitted to the percutane-
ous technique and thus avoid surgery. Certainly, these patients could also suffer from 
cryptogenic strokes and migraine, however, most of them usually require intervention 
because of hemodynamic reasons. 
The technique of percutaneous closure of a PFO or an ASD performed by adult inter-
ventional cardiologists is indeed a relatively simple and swift procedure of right heart 
catheterization, carried out from the groin area via the femoral vein with use of local 
anesthesia. Complications related to the procedure are limited to ≤1-3.4%. Due to this 
paradigm of technological progress, a rapid growth of procedures of percutaneous 
closure of ASD and PFO has been noted over the last decade, particularly over the 
recent 4-5 years. Nevertheless, one has to resist in widely and hastily adopting such 
methods before further strong evidence becomes available via randomized prospec-
tive studies.
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C R Y p T O g E N I C  S T R O K E S  A N D  p A T E N T 
F O R A M E N  O V A L E - p F O
Over the recent years, significant progress has been ac-
complished in the percutaneous management of endocardial 
communications, thus obviating the need for open heart sur-
gery procedures. Among these, a rapid growth of procedures 
of percutaneous closure of atrial secundum defects (ASD) 
and patent foramen ovale (PFO) has been noted, particularly 
in young patients with cryptogenic strokes and/or migraine 
headaches.1-3
Cerebrovascular accidents or strokes are the third cause 
of death following cardiovascular events and cancer. It is 
estimated that approximately 750 000 strokes occur yearly 
in the USA, accounting for a 27% mortality rate. Among 
these, around 600 000 strokes are considered ischemic in 
origin and 10-40% of them are considered cryptogenic, i.e. 
of unknown cause or source.4,5 It is in this group of patients 
with a cryptogenic stroke that the prevalence of a PFO is 
found to be increased to approximately 50% compared with 
a 25%-30% prevalence rate in the general population,6-8 a 
fact that leads to a plausible assumption that 30000-120000 
strokes could potentially be attributed to a PFO, most likely 
due to paradoxical embolism.7,9-13 It is estimated that the risk 
for an embolic stroke due to the presence of a PFO may be 
9-fold higher than that related to hypertension, diabetes or 
hypercholesterolemia.6,9 Furthermore, in the presence of an 
interatrial septal aneurysm (IASA), this risk culminates to even 
a 30-fold increase.8 Magnetic resonance imaging (MRI), and 
not computed tomography (CT) scanning, is considered the 
most appropriate imaging technique to display the cerebral 
infarcts.14 In certain cases in the literature, thrombus has been 
“caught in the act”,15,16 i.e. straddling the PFO, in its passage 
from the right to the left circulation, necessitating surgery 
for its removal.
The diagnosis of a PFO demands a transesophageal echocar-
diography (TEE)17 study assisted by a “bubble study”, whereby 
a rapid injection of agitated saline or other contrast material 
via the antecubital vein can demonstrate the right-to-left 
passage of microbubbles of saline or contrast directly or after 
Valsalva maneuvering. An alternate method is a transcranial 
Doppler study, when the flow of the middle cerebral artery 
is disturbed from the right-to-left passage of microbubbles of 
the agitated saline or other contrast material again injected 
via the antecubital vein; of course, the right-to-left shunting 
is thus confirmed but the level of communication (atrial or 
ventricular or other) is not visualized with this technique. 
In cases where clinical suspicion is high (e.g. in presence of 
IASA) but these contrast studies are non-diagnostic or nega-
tive, repeat injections via the femoral vein may enhance the 
diagnosis, particularly in the presence of a Eustachian valve 
in the right atrium; less commonly, probing the inter-atrial 
septum with a catheter during right heart catheterization, e.g. 
during an electrophysiology study or an ablation procedure, 
can reveal a PFO.
The management of patients with a cryptogenic stroke 
(permanent or transient) and a PFO is currently based on 
antithrombotic or anti-platelet therapy,18,19 however the re-
currence rate remains high (4-25%), a fact that has led to the 
recommendation of percutaneous PFO closure, which is now 
effected via a simple and relatively safe technique, which ap-
pears to reduce recurrences to 0-5%.20,21 However, the studies 
which provide such favorable data are only retrospective and 
data from prospective randomized studies that compare the 
two therapeutic approaches are still lacking. Recruitment of 
patients into such studies is slow, due to the fact that patients 
and physicians alike are reluctant to participate, since they 
intuitively opt for PFO closure as they consider it a more 
secure therapeutic modality rather than continuing medical 
therapy. Only though when such evidence-based data become 
available, will this mater of appropriate use of percutaneous 
PFO closure be finally and more definitively settled. All these 
notwithstanding, there has been an exponential increase of 
percutaneous procedures by a factor of 5- to 30-fold increase 
over the last decade, particularly over the recent 4-5 years.1,2 
In our department, the program of percutaneous closures 
was started 4 years ago and counts around 55 procedures, all 
performed successfully; however, a hesitant referral pattern 
of such patients by their neurologists who usually first see and 
manage them is quite obvious and largely justified due to the 
incomplete data of evidence-based medicine, mainly related 
to randomized prospective studies, comparing this invasive 
approach with the alternative conservative approach with use 
of antithrombotic agents.
According with current guidelines of medical societies, such 
as the American College of Chest Physicians-ACCP, American 
Heart Association-AHA/American Stroke Association-ASA, 
and American Academy of Neurology - AAN, the evidence 
for PFO closure is still incomplete and mainly anti-platelet or 
anticoagulant therapy (the latter in presence of known deep 
vein thrombosis or thrombophilia) is recommended.22 They 
also encourage patient participation in prospective randomized 
study protocols, while they make mention (American Heart 
Association/American Stroke Association) for consideration of 
percutaneous closure in cases of recurrences despite medical 
therapy. However, when these options are put before a patient 
and his or her family, in the majority of cases an interventional 
approach is selected after a first stroke, rather than a life-long 
antithrombotic therapy, since very few settle with the idea of 
a remaining higher risk for recurrence. The data currently 
available from several comparative, albeit non-randomized, 
studies demonstrate a significant difference between the two 
approaches with regards to recurrences, indicating a much 
smaller percentage of recurrent stroke (0-4.9%) following 
PFO closure compared with the recurrence rate (3.8-12%) of 
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pharmacotherapy.3,18-21
Certainly, one must emphasize that the PFO may sim-
ply serve in most cases as the passage gate of a right-sided 
thrombus to the systemic circulation leading to paradoxical 
embolism, and in very few one may suspect that there may be 
in situ thrombosis, particularly in large and long serpentine 
PFO tunnels,23 thus becoming imperative in most cases to 
search for the source or cause of thromboembolism, such as 
deep vein thrombosis (with use of Doppler ultrasound exami-
nation) or thrombophilia (e.g. associated with protein C or S 
deficiency, factor V Leiden, antiphospholipid antibody, etc.). 
If, indeed, such a thrombophilic state or thrombo-embolic 
source exists, percutaneous PFO closure does not cure or 
eliminate the problem, since a paradoxical embolic episode 
may be prevented, but there will remain a continuous risk of 
a serious pulmonary embolic episode, and thus the need for 
continuing anticoagulation therapy.3
p F O  A N D  M I g R A I N E
Beyond the risk of a recurrent cryptogenic stroke due to 
paradoxical embolism, there are, of course, other reasons 
for PFO closure, such as diver’s disease,24,25 the syndrome of 
tachypnea and desaturation in upright position (tachypnea-
orthodeoxia),6 the “economy class” syndrome,10 the obstructive 
sleep apnea syndrome,26 the multiple infarct dementia,11 or 
even myocardial infarction due to paradoxical embolism,22 
etc. Interestingly, after the fortuitous observation of reduc-
tion or elimination of migraine symptoms in patients with 
cryptogenic stroke undergoing percutaneous PFO closure, 
a heated discussion has ensued in the literature regarding 
the association of migraine with a PFO.9,27-40 One could at-
tribute this association to substances such as serotonin, or to 
microthrombi crossing the PFO and bypassing the pulmonary 
circulation, a place of inactivation or neutralization, and these 
substances or other ones emanating from platelets produce 
vasoactive disturbances in the cerebral circulation with sub-
sequent migrainous symptoms. Indeed, it is well known to 
neurologists that in a good number of patients afflicted with 
migraine, magnetic resonance imaging (MRI) of the brain 
discloses areas with “silent” infarcts, which could possibly 
be related to the presence of a PFO. Nevertheless, it is a fact 
that several publications report a significant reduction or even 
elimination of migraine symptoms after a percutaneous device 
closure of a PFO in an impressive number of cases ranging 
from 30% to 80%. These, of course, were all observational 
or retrospective data. However, there, indeed, seems to be 
an association of migraine with a PFO since the migraine 
incidence increases from ~12% in the general population to 
27-52% in patients with cryptogenic stroke and PFO. On the 
other hand, the presence of a PFO increases from 27% in the 
general population to 50% in migraine sufferers, particularly 
those with typical migraine associated with an aura. Of course, 
the issue remains controversial in the absence of randomized 
prospective data associating migraine with a PFO and indicating 
a better outcome with percutaneous PFO closure. Indeed, the 
only prospective randomized trial available (the MIST trial)41 
failed to show conclusively the superiority of PFO closure to 
medical treatment with regards to elimination of migraine in 
147 patients randomized to a PFO closure or sham procedure. 
Nevertheless, a greater percentage (42%) of patients improved 
amongst those receiving the device compared to those who 
did not (23%). An argument has been put forth that that the 
procedure was carried out with a suboptimal device, but this 
remains to be proven.
A T R I A L  S E C u N D u M  D E F E C T - A S D
Another large group of patients undergoing percutane-
ous closure of an interatrial communication are those with 
an ASD. The majority of these patients, at least those having 
defects as large as 35-38 mm and an adequate rim to sup-
port a closure device, can now be successfully submitted 
to the percutaneous technique and thus avoid surgery.42-44 
Certainly, these patients could also suffer from cryptogenic 
strokes and migraine, however, most of them usually require 
intervention because of hemodynamic reasons such as large 
right-to-left shunting (Qp/Qs >1.5:1.0) leading to right ven-
tricular dilation and dysfunction. Intervention has to occur 
FIguRE 1. Fluoroscopic appearance (left anterior oblique-
LAO projection) of a PFO closure device with the two disks 
held together via a thin trunk, deployed, the smaller one in the 
left atrium, and the larger one in the right atrium, bringing in 
contact (close apposition) the two membranous parts of the in-
teratrial septum. Complete closure with impermeability from 
full endothelialization is achieved within 3-6 months.
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before pulmonary hypertension develops (with pulmonary 
pressure>70% systemic pressure) and pulmonary resistance 
increases excessively (beyond 5 units Wood/m2), all leading to 
reversal of flow (Eisenmenger syndrome). Symptoms attrib-
uted to ASD comprise easy fatiguability, general weakness, 
dyspnea on exertion and/or at rest, syncope or palpitations. 
Finally, atrial septal defect of the primum or sinus venosus 
type remain surgical diseases.
p E R C u T A N E O u S  C L O S u R E
The technique of percutaneous closure of a PFO or an 
ASD performed by adult interventional cardiologists is indeed 
a relatively simple and swift procedure of right heart catheter-
ization, carried out from the groin area via the femoral vein 
with use of local anesthesia.22 This method is quite different 
from that employed by pediatric cardiologists, who use general 
anesthesia and guidance by TEE throughout the procedure. In 
contrast, in the adult catheterization laboratory the procedure 
is carried out with use of local anesthesia and is only guided by 
fluoroscopy and contrast material injection, occasionally aided 
by use of intracardiac echocardiography. First, one gets access 
to the left atrium via the PFO or the ASD with use of a long 
guidewire. The longest delay indeed relates to the time required 
to cross the interatrial communication, which occasionally 
may be tedious due to an elongated and serpentine tunnelous 
formation of a PFO. The latter is further facilitated with use 
of precurved or steerable catheters. After the passage of the 
wire to the left atrium, a guiding catheter is advanced over 
the wire and secured in place and through this catheter the 
closure device is introduced into the left atrium. The closure 
device has two disks joined with a central axis or trunk (Figure 
1). One disk is deployed in the left atrium, pulled back to the 
PFO or ASD until it gets stacked, and then the second disk is 
deployed in the right atrium. Subsequently, contrast material 
is injected through the guide catheter to check the position 
and confirm the absence of right-to-left shunting. Then the 
closure device is released from the holding device and its posi-
tion re-checked with a new contrast injection. The duration 
of the whole procedure takes approximately 10-15 minutes 
for the PFO closure. For the ASD closure, additional time is 
usually required, as there is need to make further measure-
ments with use of a balloon to precisely size the defect and 
select the appropriate device, before initiating the insertion 
procedure (Figure 2).
The patient stays in the hospital for only 1-2 days. Pre-treat-
ment with aspirin (100-325 mg/d) and clopidogrel (75 mg/d) is 
used for 3-5 days before the procedure. This antithrombotic 
regimen is continued for 3-6 months afterwards, which is until 
complete endothelialization of the device is accomplished and 
thus the thromboembolic risk is obviated. A bolus of heparin 
injection (50-100 u/kg) and 2-3 doses of prophylactic antibi-
otic are administered peri-procedurally. A new TEE exam is 
performed the next day to confirm proper device position. It 
is occasionally possible to observe some degree of interatrial 
shunting during this examination as each of the device’s disks 
is really a sieve, while full impermeability is achieved at 3-6 
months with full device endothelialization. During this critical 
3-6 month period, prophylactic antibiotic treatment is recom-
mended in case of dental or other procedures.
Complications related to the procedure are limited to 
<1-3.4% 3,43 and comprise mainly reversible problems at the 
site of access in the groin (bleeding or hematomas), but more 
serious adverse effects may occur, such as device dislodgement 
and embolization, cardiac tamponade, air embolism and atrial 
tachyarrhythmias. Occasionally, thromboembolic complica-
tions and late cardiac perforation from device erosion have 
rarely been reported.
N E W  T E C H N I q u E S
Novel percutaneous closure systems promise a smaller 
device volume on the left side, easier device manipulation 
and complete communication closure with a safer technique 
and elimination of thromboembolic complications. Of course, 
the existing closure systems have already minimal or absent 
thromboembolic risk, especially if a lege artis technique is 
employed with avoidance of endocardial thrombi formation 
during use and manipulation of guide wires and catheters. New 
bioabsorbable devices are being tested,45 while novel methods 
of fusion of the two atrial membranes (primum and secundum 
FIguRE 2. Fluoroscopic appearance (LAO projection) of an 
ASD closure device with the two disks held together with a thick 
trunk, which covers completely the atrial defect. Injection of 
contrast material in the right atrium shows the absence of right-
to-left passage and thus the complete coverage and closure of 
the defect. 
HOSPITAL CHRONICLES 4(4), 2009
156
part of the interatrial septum) are under investigation with 
use of radiofrequency energy, but have only produced mod-
est success todate, in hope to further perfect such techniques 
and thus obviate the need for foreign material implantation 
in the future.
C O N C L u S I O N
As up to 25% of patients with a cryptogenic stroke may 
have a recurrence within 4 years of the first event despite 
antithrombotic pharmacotherapy and because the presence 
of a PFO represents a congenital defect which can be easily 
remedied, several experts believe that the percutaneous closure 
of the PFO should be the treatment of choice in patients with 
cryptogenic stroke and a PFO even after the first event. Over 
the last several years, there has been a great technological 
progress in percutaneous PFO devices and closure techniques. 
Nevertheless, one has to resist in widely and hastily adopting 
such methods before further strong evidence becomes available 
via randomized prospective studies. At the same time, attempts 
are continued in developing safer and more efficacious closure 
devices with fewer or no metallic elements or with bioabsorb-
able material. Ideally, physicians should be able to discern high 
risk patients before they develop their first stroke and thus 
prevent it by proceeding to percutaneous complete closure 
with use of a device made from material that conforms well to 
both sides of the atrial septum and has no risk of thrombosis, 
erosion, infection, or arrhythmias. Prospective randomized 
trials comparing pharmacotherapy to device closure are under 
way,22 but their completion is delayed and patient recruitment 
is difficult46 as the incidence of recurrent stroke is low in young 
patients. Meanwhile, as the occurrence of device complications 
is decreasing and simpler and safer and more reliable devices 
are developed, the threshold of percutaneous closure rather 
decreases, a fact that has become apparent in recent years 
from the exponentially increasing number of percutaneous 
interventions for PFO closure worldwide.1,2,47
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